AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 182 min read$LABT

A new gel for infected diabetic foot ulcers is ready for a clinical trial

Lakewood-Amedex Biotherapeutics (LABT) received approvals to start a Phase 2a trial for Nu-3, a gel treating infected diabetic foot ulcers. The trial follows positive preclinical data and aligns with federal antimicrobial resistance mandates. LABT stock rose 3.55% on the news, with heavy trading volume.

Original reporting
stocktitan.net
Published Sep 18, 2026, 12:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 12:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$LABT
Bullish
medium confidence
Mentioned
$LABT
Relevance
7/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$LABTBullishMed
01

Why it matters

The IRB approval enables the first human efficacy assessment, a key catalyst for the company's pipeline and valuation.

02

Market read

First‑time trial start news for a micro‑cap biotech; likely to generate short‑term price movement.

03

What to watch

Funding runway and competition from larger antibiotic developers could constrain long‑term upside.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Lakewood-Amedex Biotherapeutics is a clinical‑stage company developing broad‑spectrum antimicrobials. The Nu-3 gel targets infected diabetic foot ulcers, a high‑need indication.

Company-level read

Ticker impact

$LABTBullishMedium confidence
Context

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) received IRB approval and is ready to start its Phase 2a trial of Nu-3 for infected diabetic foot ulcers.

Expected impact

Potential upside of 5‑10% over the next week if early data appear positive.

Evidence & confidence

Biotech stocks often rally on trial start announcements, especially when the market reaction is already positive (+3.55%).

Market effects

Sector

Highlights growing interest in antimicrobial‑resistant therapies, may benefit other biotech firms in the anti‑infection space.

Regional

US biotech sector sees modest boost; limited broader market effect.

Global

Limited to investors tracking clinical‑stage biotech developments.

Counterpoint

What could challenge this read

Trial may face delays or negative data; early hype could be premature.

Key entities

  • company
    Lakewood-Amedex Biotherapeutics Inc.

    Clinical‑stage biotech developing the Bisphosphocin® class of antimicrobials.

  • product
    Nu-3

    Proprietary topical gel intended to treat infected diabetic foot ulcers.

Read at source← All news

Also covered by

1 outlet

Related articles

OCT 7
$LABTMedAI 8/10

A compound inhibited up to 97% of E. coli growth in rodents; the control group showed no effect.

Lakewood-Amedex Biotherapeutics (LABT) reported preclinical data showing its Bisphosphocin compound Nu-8 inhibited up to 97% of E. coli growth in rodents. Aerosol formulations also showed activity against pulmonary infections. The company plans further development to identify a clinical candidate. Nu-3 is in a Phase 2a trial for diabetic foot ulcers, with topline data expected in Q1 2027.

stocktitan.net2 min
OCT 7
$LABTMedAI 8/10

Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds

Lakewood-Amedex Biotherapeutics reported positive preclinical data for its Bisphosphocin® compounds, showing up to 97% inhibition of E. coli growth in urinary tract infections and activity against resistant bacteria in pulmonary infections. The company's lead candidate, Nu-3, is in a Phase 2a trial for diabetic foot ulcers, with results expected in Q1 2027. The Bisphosphocin® class aims to combat antibiotic-resistant strains.

prnewswire.com2 min
SEP 28
$LABTMedAI 8/10

Lakewood-Amedex doses first patient in Phase 2a trial for Diabetic foot infections

Lakewood-Amedex Biotherapeutics dosed the first patient in a Phase 2a trial for Nu-3, a gel treating mildly infected diabetic foot ulcers. The trial will assess safety, efficacy, and optimal dosage. Results are expected in Q1 2027, with potential Phase 2b advancement if successful. According to the company, Nu-3 aims to reduce antimicrobial resistance by targeting infections locally.

proactiveinvestors.com2 min
SEP 24
$LABTLow

Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) has dosed the first patient in its Phase 2a clinical trial for Nu-3, a topical antimicrobial gel for infected diabetic foot ulcers. The trial aims to evaluate safety and efficacy of three gel concentrations, with topline data expected in Q1 2027. Nu-3 is part of the company's Bisphosphocin® antimicrobial platform.

prnewswire.com2 min
SEP 21
$LABTMedAI 8/10

Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) received IRB approvals and clinical site readiness to start a Phase 2a trial for its lead product, Nu-3, treating infected diabetic foot ulcers. The trial aims to evaluate Nu-3's safety and efficacy, building on positive preclinical data. The company aims to address antibiotic-resistant bacterial strains with its Bisphosphocin® class of antimicrobials.

insidermonkey.com2 min